Researchers have come up with a web-based calculator named ‘CTS5 calculator’ that can help you predict the long-term risk of breast cancer.
The web-based calculator can be used to decide which patients are at high enough risk of their cancer returning after receiving the standard five years of endocrine.
It could also predict which patients are at low risk of recurrence, and so can avoid any further therapy along with the potential adverse side effects.
According to the research, over the last three decades, there has been a major increase in the rate of invasive breast cancer in Western countries.
However, hormone therapy can have significant side effects for some patients, including weakness of bone tissue, and exacerbation of menopausal symptoms. Oncologists along with patients have to decide after five years of hormone treatment whether extending this type of therapy is worthwhile and appropriate.
After reviewing the data from two previously published studies, the researchers provided information on 11,446 postmenopausal women with ER-positive breast cancer who had received five years of hormone therapy.
To investigate the validity of the tool, researchers then tested CTS5 against data from the second study. As a result, CTS5 was shown to be able to accurately separate women into groups of a low, intermediate, or high risk of developing a late distant recurrence breast cancer after five years of hormone therapy.